RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MARINARO L
Collezione ASL Città di Torino

Items : 14

Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV. in International journal of antimicrobial agents / Int J Antimicrob Agents. 2024 Jun;63(6):107137. doi: 10.1016/j.ijantimicag.2024.107137. Epub 2024 Ma

2024
ASL Città di Torino

D'Avolio A; Di Perri G; Bonora S; Trunfio M; Antonucci M; Marinaro L; Avataneo V; Mula J; Palermiti A; Manca A; Cusato J; Calcagno A;

Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria? in Antimicrobial agents and chemotherapy / Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0023424. doi: 10.1128/aac.00234-24. Epub 2024 May 24.

2024
ASL Città di Torino

D'Avolio A; Marinaro L; Alladio F; Ponzetta L; Cat Genova E; Quaranta M; Stroffolini G; Venuti F; de Nicolò A; Gaviraghi A; Calcagno A;

Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants. in Diagnostics (Basel, Switzerland) / Diagnostics (Basel). 2023 Jan 12;13(2):295. doi: 10.3390/diagnostics13020295.

2023
ASL Città di Torino

D'Avolio A; Bonora S; Mula J; Di Perri G; Manca A; Palermiti A; Marinaro L; Trunfio M; Antonucci M; Avataneo V; Cusato J; Calcagno A;

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. in Thrombosis research / Thromb Res. 2020 Dec;196:432-434. doi: 10.1016/j.thromres.2020.09.039. Epub 2020 Oct 8.

2020
ASL Città di Torino

Bonora S; Roccatello D; Sciascia S; Lipani F; Gaviraghi A; Trentalange A; Marinaro L; Alcantarini C; Cabodi D; Salvador E; Trunfio M; Di Perri G; Calcagno A;

Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. in The pharmacogenomics journal / Pharmacogenomics J. 2020 Apr;20(2):202-212. doi: 10.1038/s41397-019-0109-x. Epub 2019 Oct 16.

2020
ASL Città di Torino

Cusato J; Calcagno A; Marinaro L; Avataneo V; D?Avolio A; Di Perri G; Bonora S;

Safety and efficacy of daclatasvir at doses other than 60?mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver / Dig Liver Dis. 2020 Apr;52(4):447-451. doi: 10.1016/j.dld.2019.12.007. Epub 2020 Jan 17.

2020
ASL Città di Torino

Rossotti R; Tavelli A; Bonora S; Cingolani A; Lo Caputo S; Saracino A; Soria A; Marinaro L; Uberti-Foppa C; Mussini C; Puoti M; d'Arminio Monforte A;

Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. in Antiviral therapy / Antivir Ther. 2020;25(6):327-333. doi: 10.3851/IMP3377.

2020
ASL Città di Torino

Trunfio M; Salvador E; Gaviraghi A; Audagnotto S; Marinaro L; Motta I; Casciaro R; Ghisetti V; Fava C; Bonora S; Di Perri G; Calcagno A;

The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. in Antiviral therapy / Antivir Ther. 2018;23(5):451-456. doi: 10.3851/IMP3221.

2018
ASL Città di Torino

Bigliano P; Calcagno A; Lucchini A; Audagnotto S; Montrucchio C; Marinaro L; Alcantarini C; Ghisetti V; Di Perri G; Bonora S;

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology / J Clin Virol. 2017 Feb;87:30-36. doi: 10.1016/j.jcv.2016.11.015. Epub 2016 Dec 1.

2017
ASL Città di Torino

Marinaro L; Calcagno A; Ripamonti D; Cenderello G; Pirriatore V; Trentini L; Salassa B; Bramato C; Orofino G; D'Avolio A; Rizzi M; Di Perri G; Rusconi S; Bonora S;

Efavirenz pharmacogenetics in a cohort of Italian patients. in International journal of antimicrobial agents / Int J Antimicrob Agents. 2016 Feb;47(2):117-23. doi: 10.1016/j.ijantimicag.2015.11.012. Epub 2015 De

2016
ASL Città di Torino

Di Perri G; Leggieri A; Allegra S; Marinaro L; Bonora S; Calcagno A; Simiele M; Tomasello C; Cusato J; D'Avolio A; Cusato J; Tomasello C; Simiele M; Calcagno A; Bonora S; Marinaro L; Leggieri A; Allegra S; Di Perri G; D'Avolio A;

Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. in Current HIV research / Curr HIV Res. 2016;14(1):54-60. doi: 10.2174/1570162x13666150929112135.

2016
ASL Città di Torino

Calcagno A; Montrucchio C; Capetti A; Guaraldi G; Cenderello G; Calza L; Lanzafame M; Marinaro L; Tettoni MC; Trentini L; D'Avolio A; Di Perri G; Bonora S;

HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients. in AIDS research and human retroviruses / AIDS Res Hum Retroviruses. 2015 Oct;31(10):999-1008. doi: 10.1089/AID.2015.0102. Epub 2015 Aug 6.

2015
ASL Città di Torino

Calcagno A; Motta I; Ghisetti V; Lo Re S; Allice T; Marinaro L; Milia MG; Tettoni MC; Trentini L; Orofino G; Salassa B; Di Perri G; Bonora S;

Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. in Antiviral research / Antiviral Res. 2014 Aug;108:44-7. doi: 10.1016/j.antiviral.2014.05.009. Epub 2014 May 23.

2014
ASL Città di Torino

Calcagno A; Marinaro L; Nozza S; Aldieri C; Carbone A; Ghisetti V; Trentalange A; D'Avolio A; Castagna A; Di Perri G; Bonora S;

Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. in Current HIV research / Curr HIV Res. 2014;12(5):339-46. doi: 10.2174/1570162x12666140807151616.

2014
ASL Città di Torino

Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S;